Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Antiphospholipase A₂ receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.

Behnert A, Schiffer M, Müller-Deile J, Beck LH Jr, Mahler M, Fritzler MJ.

J Immunol Res. 2014;2014:143274. doi: 10.1155/2014/143274. Epub 2014 Apr 9.

2.

An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.

Behnert A, Fritzler MJ, Teng B, Zhang M, Bollig F, Haller H, Skoberne A, Mahler M, Schiffer M.

PLoS One. 2013 Apr 29;8(4):e61669. doi: 10.1371/journal.pone.0061669. Print 2013.

3.

Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).

Radice A, Trezzi B, Maggiore U, Pregnolato F, Stellato T, Napodano P, Rolla D, Pesce G, D'Amico M, Santoro D, Londrino F, Ravera F, Ortisi G, Sinico RA.

Autoimmun Rev. 2016 Feb;15(2):146-54. doi: 10.1016/j.autrev.2015.10.004. Epub 2015 Oct 23. Review.

PMID:
26527329
4.

Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.

Segarra-Medrano A, Jatem-Escalante E, Quiles-Pérez MT, Salcedo MT, Arbós-Via MA, Ostos H, Valtierra N, Carnicer-Cáceres C, Agraz-Pamplona I.

Nefrologia. 2014 May 21;34(3):353-9. doi: 10.3265/Nefrologia.pre2013.Dec.12291. Epub 2014 Feb 10. English, Spanish.

5.

[The relationship between anti-phospholipase A2 receptor antibody and idiopathic membranous nephropathy].

Lin W, Li H, Li X, Qin Y, Su Y, Yu Y, Guan Y, Duan L, Li Y, Wen Y, Li X.

Zhonghua Nei Ke Za Zhi. 2015 Sep;54(9):783-8. Chinese.

PMID:
26674797
6.

Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.

Kumar V, Ramachandran R, Kumar A, Nada R, Suri D, Gupta A, Kohli HS, Gupta KL, Jha V.

Nephrology (Carlton). 2015 Aug;20(8):572-5. doi: 10.1111/nep.12478.

PMID:
26194981
7.

PLA2R and membranous nephropathy: A 3 year prospective Australian study.

Hill PA, McRae JL, Dwyer KM.

Nephrology (Carlton). 2016 May;21(5):397-403. doi: 10.1111/nep.12624.

PMID:
26369693
8.

Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy.

Quintana LF, Blasco M, Seras M, Pérez NS, López-Hoyos M, Villarroel P, Rodrigo E, Viñas O, Ercilla G, Diekmann F, Gómez-Roman JJ, Fernandez-Fresnedo G, Oppenheimer F, Arias M, Campistol JM.

Transplantation. 2015 Aug;99(8):1709-14. doi: 10.1097/TP.0000000000000630.

PMID:
25675198
9.

Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.

Gupta G, Fattah H, Ayalon R, Kidd J, Gehr T, Quintana LF, Kimball P, Sadruddin S, Massey HD, Kumar D, King AL, Beck LH Jr.

Clin Transplant. 2016 Apr;30(4):461-9. doi: 10.1111/ctr.12711. Epub 2016 Mar 11.

PMID:
26854647
10.

Detection and monitoring PLA2R autoantibodies by LIPS in membranous nephropathy.

Burbelo PD, Beck LH Jr, Waldman M.

J Immunol Methods. 2017 May;444:17-23. doi: 10.1016/j.jim.2017.02.001. Epub 2017 Feb 4.

PMID:
28167276
11.

The accuracy of the anti-phospholipase A2 receptor antibody in the diagnosis of idiopathic membranous nephropathy: a comparison of different cutoff values as measured by the ELISA method.

Dou Y, Zhang L, Liu D, Wang C, Quan S, Ma S, Xiao J, Cheng G, Liu Z, Zhao Z.

Int Urol Nephrol. 2016 Jun;48(6):845-9. doi: 10.1007/s11255-016-1263-6. Epub 2016 Mar 26.

PMID:
27017339
12.
14.

Anti-Phospholipase A2 Receptor Antibody as Prognostic Indicator in Idiopathic Membranous Nephropathy.

Kim YG, Choi YW, Kim SY, Moon JY, Ihm CG, Lee TW, Jeong KH, Yang SH, Kim YS, Oh YJ, Lee SH.

Am J Nephrol. 2015;42(3):250-7. doi: 10.1159/000440983. Epub 2015 Oct 20.

PMID:
26484659
15.

[Preliminary results of research on a new marker of idiopathic membranous nephropathy: anti-PLA2R].

Kozioł M, Sikora A, Kozioł-Montewka M, Smarz-Widelska I, Orłowska-Kowalik G, Pyszna W, Załuska W, Ksiazek A.

Pol Merkur Lekarski. 2014 Mar;36(213):171-4. Polish.

PMID:
24779214
16.

Anti-PLA2R Antibodies in Chinese Patients with Membranous Nephropathy.

Li X, Wei D, Zhou Z, Wang B, Xu Y, Pan J, Yang C, Lu J, Qiu Y.

Med Sci Monit. 2016 May 15;22:1630-6.

17.

Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice?

Hofstra JM, Wetzels JF.

Neth J Med. 2012 Apr;70(3):109-13. Review.

18.

Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.

Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS.

PLoS One. 2013 Apr 26;8(4):e62151. doi: 10.1371/journal.pone.0062151. Print 2013.

19.

Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.

Kao L, Lam V, Waldman M, Glassock RJ, Zhu Q.

J Am Soc Nephrol. 2015 Feb;26(2):291-301. doi: 10.1681/ASN.2013121315. Epub 2014 Sep 9.

20.

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.

Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, Brenchley PE.

Kidney Int. 2013 May;83(5):940-8. doi: 10.1038/ki.2012.486. Epub 2013 Jan 30.

Supplemental Content

Support Center